1295P Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)

MLA

M. Saggese, et al. “1295P Osimertinib vs Comparator EGFR-TKI as First-Line Treatment for EGFR Mutated (EGFRm) Advanced NSCLC: FLAURA China Study Overall Survival (OS).” Annals of Oncology, vol. 31, Sept. 2020, pp. S838–39. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1609.

APA

M. Saggese, Yong He, Wenqian Li, Andrew Walding, Ying Cheng, Qin Zhou, Bu-Hai Wang, H-L. Zhang, Yu-Zhen Liu, S.S. Ramalingam, R. Su, Chunling Liu, & X. Huang. (2020). 1295P Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS). Annals of Oncology, 31, S838–S839. https://doi.org/10.1016/j.annonc.2020.08.1609

Chicago

M. Saggese, Yong He, Wenqian Li, Andrew Walding, Ying Cheng, Qin Zhou, Bu-Hai Wang, et al. 2020. “1295P Osimertinib vs Comparator EGFR-TKI as First-Line Treatment for EGFR Mutated (EGFRm) Advanced NSCLC: FLAURA China Study Overall Survival (OS).” Annals of Oncology 31 (September): S838–39. doi:10.1016/j.annonc.2020.08.1609.